216

CHAPTER – 7

REFERENCES

217

1. Sastry.S.V., Nyshadham.J.R. and Fix.J.A. Recent technological

advances in oral Drug delivery – a review. Pharm Sci Technol Today,

3, 2000; pp. 138–145.

2. Rathbone.M.J., Hadgraft.J. and Roberts.M.S. Modified release drug

delivery technology. Marcel Dekker, 2003; New York.

3. Lordi.N.G. Sustained release dosage forms. In: Lachman, L.,

Lieberman, The theory and practice of industrial pharmacy, 3rd edn.

Varghese Publishing House, Bombay, 1987; pp.430– 456.

4. Chiao.C.S.L. and Robinson.J.R. Sustained release drug delivery

systems. Remington: the science and practice of pharmacy, vol. II.

Mack Publishing Company, Easton, PA, pp. 1995; 1660–1675.

5. Kydonieus.A.F. Fundamental concepts of controlled release. In:

Controlled release technologies: Methods, theory, and applications.

vol. I. CRC, Florida, 1990; pp. 1–19.

6. Lordi N.G. "Sustained release dosage form" chapter 14 in "Theory and

practice of Industrial Pharmacy" , 3rd edition, Varghese Publishing

House, 1991;p. 430-431.

7. Welling.P.G., Dobrinska.M.R. Chapter 6 in "Controlled drug delivery:

Fundamentals and applications”, 2nd edition, Marcel Dekker Inc.,

Volume 29, 1978: pp.254-289.

8. Madhukat, Mansukalal.D, Milind, Dattatraya Joshi and Bharat

Pravinchandra. M. Pharmaceutical composition for controlled drug

delivery system, patent No: US 7,157,100 B2, ; 2007.

218

9. James Swarbrick, James C. Boylan. Encyclopedia of Pharmaceutical

Technology.2007; pp. 369-394.

10. Venkataraman Daar.S N, Chester.A, Kliener.L. An overview of

Controlled release systems, Handbook of Pharmaceutical Controlled

release technology, Marcel dekker Inc: 2000; p p.1-30.

11. Gilberts, Banker, Neil R. Anderson, Sustained release dosage forms;

The Theory and Practice of Industrial Pharmacy, 2001; 3rd edition .pp.

430- 456.

12. Rudnic E. and Schawartz J.B, Oral solid dosage forms, Remington’s

Pharmaceutical Sciences, Mack Publishing Company, Easton,

Pennsylvania,1965; pp. 2000.

13. Ahmad, A. B., Bennett, P. N. & Rowland, M. Influence of route of

hepatic administration on drug availability. Journal of Pharmacology

and Experimental Therapeutics 230, 1984; pp.718—725.

14. Joseph Robinson. R, Vincent H. L. Lee, Controlled drug delivery

fundamentals and applications, Marcel Dekker Inc, New York:3-

61.2002.

15. Birkett.D.J. Half-life, Pharmacokinetics made easy, Australian

prescriber,. 11: 1996; p.57-59.

16. Hogan, J.E. Hydroxypropylmethylcellulose sustained release

technology. Drug Dev Ind Pharm, 1989; pp. 975–999.

17. Velasco.M.V., Ford. J.L., Rowe.P. and Rajabi-Siahboomi, A.R.

Influence of drug: HPMC ratio, drug and Polymer particle size and

compression force on the release of diclofenac sodium from HPMC

tablets. J Control Release, 1999; 57, pp. 75–85.

219

18. Mitchell. K., Ford, J.L., Armstrong, D.J., Elliott, P.N., Hogan, J.E. and

Rostron, C. The influence of drugs on the properties of gels and

swelling characteristics of matrices Containing methylcellulose or

hydroxypropylmethylcellulose. Int J Pharm, 1993; pp.165–17.

19. Brand protection: tablet shape. http://www.colorcon.com

20. Dow excipients, Methocel products. http://www.dow.com/dow

excipients/products/methocel.htm

21. Ford.J.L., Rubinstein.M.H., Changela.A. and Hogan.J.E. The influence

of pH on the dissolution of promethazine hydrochloride from hpmc

controlled release tablets. J Pharm. Pharmacol, 1985; 37, pp.115-119.

22. Levina.M., Gothoskar.A. and Rajabi Siahboomi.A. Application of a

Modeling system in the formulation of extended release hydrophilic

matrices. Pharm Technol Eur, 2006; 18, pp.20–26.

23. Alderman.D.A. A review of cellulose ethers in hydrophilic matrices for

oral controlled- release dosage forms. Int J Pharm Tech Prod Manuf,

1984; 5, pp.1–9.

24. Shah, N., Railkar, A.S., Watnanee, P., Zeng, F.-U., Chen, A., Infeld,

M.H. and Malick, A.W. Effects of processing techniques in controlling

the release rate and mechanical strength of HPMV based matrices.

Eur J Pharm Biopharm, 1996; 42, pp. 183–187.

25. Levina.M. and Rajabi Siahboomi.A. The influence of excipients on

drug Release from hydroxypropyl methylcellulose matrices. J Pharm

Sci, 2004; 93, p. 2746–2754.

220

26. Horter.D. and Dressman.J.D. Influence of physicochemical

properties on Dissolution of drugs in the gastrointestinal tract. Adv

Drug Deliv Rev, 1997;25 ,pp. 3–14.

27. Vashi.V.I. and Meyer.M.C. Effect of pH on the in vitro dissolution and

in vivo absorption of controlled release theophylline in dogs. J Pharm

Sci, 1988;77, pp. 760–774.

28. Kohri.N., Miyata.N., Takahashi.M., Endo.H., Iseki.K., Miyazaki.K.,

Takechi.S and Nomura.A. Evaluation of pH-independent sustained

release granules of dipyridamole by using gastric-acidity controlled

rabbits and human subjects. Int J Pharm, 1992; 81, pp. 49–58.

29. Tatavarti.A.S. and Hoag.S.W. Microenvironmental pH modulation

based Release enhancement of a weakly basic drug from hydrophilic

matrices. J Pharm Sci, 2006; 95, pp.1459–1468.

30. Siepe.S., Herrmann.W., Borchert.H.H., Lueckel.B., Kramer.A., Ries.A.

and Gurny.R. Microenvironmental pH and micro viscosity inside pH-

controlled matrix tablets: an EPR imaging study. J Control Release,

2006; 112, pp. 72–78.

31. Tatavarti. A.S., Mehta. K.A., Augsburger. L.L. and Hoag. S.W.

Influence of methacrylic and acrylic acid polymers on the release

performance of weakly basic drugs from sustained release hydrophilic

matrices. J Pharm Sci, 2004; 93, pp. 2319–2331.

32. Siepe.S., Lueckel.B., Kramer.A., Ries.A. and Gurny.R. Strategies for

the design of hydrophilic matrix tablets with controlled

microenvironmental pH. Int J Pharm, 2006; 316, pp. 14–20.

221

33. Streubel.A., Siepmann.J., Dashevsky.A. and Bodmeier.R. pH-

independent release of a weakly basic drug from water-insoluble and

soluble matrix tablets. Jour. of Control Release, 2000; 67, pp. 101–

110.

34. Gabr.K. Effect of organic acids on release patterns of weakly basic

drugs from inert sustained release matrix tablets. Eur J Pharm

Biopharm, 1992; 38, pp. 199–202.

35. Varma.M.V.S., Kaushal.A.M. and Garg.S. Influence of micro-

environmental pH on the gel layer behavior and release of a weakly

basic drug from various hydrophilic matrices. Journal of Controlled

Release, 2005; 103, pp. 499–510.

36. O Connor. K.M. and Corrigan. O.I. Effect of basic organic excipients

on the dissolution of diclofenac salts. J Pharm Sci, 2002; 91, pp.

2271– 2281.

37. Rao.V.M., Engh.K. and Qiu.Y. Design of pH-independent controlled

release matrix tablets for acidic drugs. Int. Jour. Pharm, 2003; 252,

pp. 81–86.

38. Michelucci.J.J., Sherman. D.M. and DeNeale, R.J.Sustained release

etodolac. US Pat. 1990; 4, 966, 768.

39. Riis.T., Bauer Brandl.A., Wagner.T. and Kranz.H. pH-independent

drug release of an extremely poorly soluble weakly acidic drug from

multiparticulate extended release formulations. Eur J Pharm

Biopharm, 2007; 65, pp.78–84.

222

40. Ruff. M.D., Kalidindi.S.R. and Sutton, J.J.E. Pharmaceutical

composition containing bupropion hydrochloride and a stabilizer. US

Pat.1994; 5, 358,970.

41. Methocel cellulose ethers technical handbook. http: // www.dow.com

/ Published Literature /192–01062.

42. Mitchell.K., Ford.J.L., Armstrong. D.J., Elliott.P.N., Rostron. C. and

Hogan.J.E. The influence of additives on the cloud point,

disintegration and dissolution of Hpmc gels and matrix tablets. Int J

Pharm, 1990; 66, pp. 233–242.

43. SarkarN. Thermal gelation properties of methyl and hydroxypropyl

methylcellulose. J Appl Polym Sci,1979; 24, 1073–1087

44. Johnson.J.L., Holinej. J. and Williams, M.D. Influence of ionic

strength on matrix integrity and drug release from hydroxypropyl

cellulose compacts. Int Jour. Pharm,1993; 90, pp. 151–159.

45. Reynolds.T.D., Mitchelle.S.A. and Balwinski.K.M. Investigation of the

effect of tab let surface area/volume on drug release from

hydroxypropylmethylcellulose controlled release matrix tablets. Drug

Dev Ind. Pharm, 2002; 28, pp. 457–477.

46. Siepmann.J., Kranz.H., Peppas.N.A. and Bodmeier.R. Calculation of

the required size and shape of hydroxypropyl methylcellulose matrices

to achieve desired drug release profiles. Int Jour Pharm, 2000; 201,

pp.151–164.

47. Colombo.P., Conte.U., Gazzaniga.A., Maggi, L., Sangalli, M.E., Peppas,

N.A. and Manna, A.L. Drug release modulation by physical

restrictions of matrix swelling. Int Jour Pharm, 1990; 63, pp. 43–48.

223

48. Colombo.P., Catellani, P., Peppas, N.A., Maggi, L. and Conte, U.

Swellling characteristics of hydrophilic matrices for controlled

release: new dimensionless number to describe the swelling and

release behavior. Int Jour Pharm, 1992; 88, pp. 99–109.

49. Levina. M., Wan, P., Jordan, M. Rajabi-Siahboomi, A.R. The influence

of film coatings on performance of hypromellose matrices.2003

http://www.colorcon.com/pharma.

50. Vuong, H., Levina, M. and Rajabi-Siahboomi, A.R. The effect of film

coating and storage conditions on the performance of metformin HCl

extended release hypromellose matrices. 2006,

http:/www.colorocon.com.

51. Tiwari.S.B., Murthy.T.K., Pai.M.R., Mehta.P.R. and Chowdary. P.B.

Controlled release formulation of tramadol hydrochloride using

hydrophilic and hydrophobic matrix system. AAPS Pharm Sci Tech,

2003; 4.pp.31.

52. Dias, V.D., Gothoskar, A.V., Fegely, K. and Rajabi-Siahboomi, A.R.

Modulation of drug release from hypromellose (HPMC) matrices:

suppression of the initial burst effect.2006,

www.colorcon.com/pharma.

53. Chien-Chi Lin , Andrew T. Metters, Advanced Drug Delivery Reviews,

58, 2006; pp.1379–1408.

54. Higuchi T. Mechanism of sustained action medication, theoretical

analysis of rate of release of solid drugs dispersed in solid matrices. J

Pharm Sci 1963; 52. pp.1145-9

224

55. J.L. Ford, M.H. Rubinstein, F. McCaul, J.E. Hogan, P. Edgar,

Importance of drug type, tablet shape and added diluents on drug

release kinetics from Hydroxypropylmethylcellulose matrix tablets.

Int. J. Pharm., 1987;40, pp. 223-234.

56. L.C. Feely, S.S. Davis, The influence of polymeric excipients on drug

release from Hydroxypropylmethylcellulose matrices, Int. J.

Pharm.1988; 41, pp. 83–90.

57. J.E. Hogan, Hydroxypropylmethylcellulose sustained release

technology, Drug Dev. Ind. Pharm. 1998; 15, p. 975–999.

58. Higuchi T. Mechanism of sustained action medication, theoretical

analysis of rate of release of solid drugs dispersed in solid matrices. J

Pharm Sci 1963; 52. pp. 1145-9

59. Peppas. N.A, Sahlin. J.J. A simple equation for the description of

solute release: coupling of diffusion and relaxation. Int J Pharm 1989;

57: p. 169-72

60. Costa.P, Lobo.J.M.S. Modeling comparison of dissolution profiles. Eur

Jour Pharm Sci. 2001; 13: pp. 123

61. Mulye.N.V, Turco.S.T. An examination of assumptions underlying the

first-order kinetic model for release of water soluble drugs from

matrices. Drug Dev Ind Pharm 1996; 2 : pp. 673-9

62. Varelas. C.G, Dixon. D.G and Steiner. C. Zero-order release from

biphasic polymer hydrogels. Journal of Controlled Release, 1995; 34:

pp. 185-92

225

63. Christensen.F.N, Hansen.F.Y and Bechgaard.H. Physical

interpretation of parameters for drug release from controlled release

dosage forms. J Pharm Pharmacol 1980; 32: pp. 580

64. Hixon.A.W and Crowell.J.H. Dependence of reaction velocity upon

surface and agitation. Ind Eng Chem 1931; 23: p. 923-31

65. Korsmeyer.R.W, Gurny.R, Doelker.E, et al. Mechanisms of solute

release from porous hydrophilic polymers. Int J Pharm 1983; 15: pp.

25-35

66. Muller.F.B, Ha.H.R, Hotz.H et al. Once a day verapamil in essential

hypertension.Br Jour Clin Pharmacol. 1986; 21:143-7S.

67. Follath.F, Ha.H.R, Schutz.E et al. Pharmacokinetics of conventional

and slow release verapamil. Br Jour Clin Pharmacol. 1986; 21:pp. 149-

153.

68. Michael Weber, MD. Clinical safety and tolerability of losartan.Clinical

Therapeutics, 19, NO. 4, 1997 .pp. 604- 616

69. McIntyre.M, S. E. Gaffe, R. A. Michaluk and J. L. Reid. Losartan, an

orally active angiotensin (AT1) receptor antagonist: a review of its

efficacy and safety in essential hypertension. Pharmacol. Vol. 74, No.

2,1997; pp. 181-194.

70. Domenic.A. Sica, Todd W.B. Gehr and Siddhartha Ghosh. Clinical

Pharmacokinetics of Losartan. Clinical harmacokinets. 2005; 44 : pp.

797-814.

71. Bottenberg.P, Cleymaet. R, De Muynck.C, et al. Development and

testing of bioadhesive, fluoride-containing slow-release tablets for oral

use. J Pharm Pharmacol. 1991; 43: pp. 457–464.

226

72. K.E. Anderson, B.R. Stevenson, and J.A. Rogers, “Folic Acid-PEO

Labeled Liposomes To Improve Gastrointestinal Absorption of

Encapsulated Agents,” Journal of Controlled Release 1999 (2–3),

pp.189-198.

73. H. Suh et al., “Regulation of Smooth Muscle Cell Proliferation Using

Paclitaxel Loaded Poly(ethylene oxide)–Poly(lactide–glycolide)

Nanospheres,” J. Biomed. Mater. Res. 1998. pp. 331–338.

74. Yeh. M.K., Davis. S.S., and A.G. Coombes, “Improving Protein Delivery

from microparticles Using Blends of Poly(DL lactide co- glycolide) and

Poly(ethylene oxide)–Poly(propylene oxide) Copolymers,” Pharm. Res.

13; 1996; pp.1693–1698.

75. L. Liu et al., “Sandwiched Osmotic Tablet Core for Nifedipine

Controlled Delivery,” Biomed.Mater. Eng.1999; 9, pp. 297–310.

76. Jovanovic. M, Jovicic.G, Duvic.Z, et al. Effect of fillers and lubricants

on acetylsalicylic acid release kinetics from eudragit matrix tablets.

Drug Dev Ind Pharm. 1997; 23(6): pp. 595–602.

77. Gupta.V.K, Beckert .T.E and Price.J.C. A novel pH- and time-based

multi unit Potential colonic drug delivery system. I. Development. Int

Jour Pharm. 2001; 213: pp. 83–91.

78. Gupta.V.K, Assmus.M.W, Beckert.T.E and Price.J.C. A novel pH- and

time based multi unit potential colonic drug delivery system. II

Optimization of multiple response variables. Int Jour Pharm. 2001;

213: pp. 93–102.

79. Umejima H, Kim N-S, Ito T, et al. Preparation and evaluation of

Eudragit gels: in vivo evaluation of Eudispert rectal hydrogel and

227

xerogel containing salicylamide. Jour Pharm Sci 1993; 82: pp.195–

199.

80. Hartman.A.W, Nesbitt.R.U, Smith.F.M and Nuessle.N.O. Viscosities of

acacia and sodium alginate after sterilization by cobalt-60. J Pharm

Sci 1975; 64: pp.802–805.

81. Tonnesen.H.H and Karlsen.J. Alginate in drug delivery systems. Drug

Dev Ind Pharm. 2002; 28(6): pp.621–630.

82. Veski.P and Marvola. M. Sodium alginates as diluents in hard gelatin

capsules containing ibuprofen as a model drug. Pharmazie. 1993; 48

(10): pp.757–760.

83. Azarmi.S, Valizadeh.H, Barzegar.J.M and Loebenberg R. ’In situ’

crosslinking of polyanionic polymers to sustain the drug-release of

acetazolamide tablets. Pharm Ind. 2003; 63(9): pp.877–881.

84. Rajaonarivony.M, Vauthier.C, Couarraze.G, et al. Development of a

new drug carrier made from alginate. Jour Pharm Sci 1993; 82(9): pp.

912–917.

85. Attia MA, ElGibaly I, Slialtout SE. Transbuccal permeation, anti

inflammatory and clinical efficacy of piroxicam formulated in different

gels. Int J Pharm, 2004; 276: pp. 11– 28.

86. Balasubramaniam. J and Pandit. J.K. Ion-activated in situ gelling

systems for Sustained release ophthalmic delivery of ciprofloxacin

hydrochloride. Drug Delivery 2003; 10(3): pp. 185–191.

87. Kubo.W, Miyazaki.S and Attwood.D. Oral sustained delivery of

paracetamol from in situ gelling gellan and sodium alginate

formulations. Int Jour Pharm 2003; 258(1–2): pp. 55–64.

228

88. Narisawa S, Yoshino H, Hirakawa Y, Noda K. Porosity-controlled ethyl

cellulose film coating. IV. Evaluation of mechanical strength of porous

ethyl cellulose film. Chem Pharm Bull 1994; 42(7): pp. 1491–1495.

89. Sadeghi F, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. Study of

drug release from pellets coated with surelease containing HPMC. Drug

Dev Ind Pharm 2001; 27(5): pp. 419–430.

90. Pollock.D and Sheskey.P. Micronized ethylcellulose: opportunities in

direct compression controlled-release tablets. Pharm Technol. 1996;

20,9: pp.120–130.

91. FAO/WHO. Evaluation of certain food additives and contaminants.

Twenty-ninth report of the joint FAO/WHO expert committee on food

additives. World Health Organ Tech Rep Ser. 1986; No. 733.

92. Bumphrey.G. ‘Extremely useful’ new suspending agent. Pharm J.

1986; pp. 237: 665.

93. Evans.B.K and Fenton May.V.K. Xanthan gum: Pharmaceutical

excipient. Pharm J 1986; 237: pp. 736–737.

94. Chollet.J.K, Jozwiakowski. M.J, Phares.K.R, et al. Development of a

topically active imiquimod formulation. Pharm Dev Technol. 1999; 4:

pp.35–43.

95. Talukdar .M, Van der Mooter G, Augustijus P. In vivo evaluation of

xanthan gum as a potential excipient for oral controlled-release matrix

tablet formulation. Int J Pharm 1998; 169: p p.105–113.

96. Lu.M.F, Woodward.L and Borodkin.S. Xanthan gum and alginate

based controlled release theophylline formulations. Drug Dev Ind

Pharm 1991; 17: pp.1987–2004.

229

97. Dhopeshwarkar. V and Zatz. J.L. Evaluation of xanthan gum in the

preparation of sustained release matrix tablets. Drug Dev Ind Pharm

1993; 19: pp. 999–1017.

98. Billa.N, Yuen.K.H, Khader.M.A and Omar.A. Gamma scintigraphic

study of the gastrointestinal transit and in vivo dissolution of a

controlled release diclofenac sodium formulation in xanthan gum

matrices. Int J Pharm 2000; 201: pp. 109–120.

99. Peh. K.K & Wong. C.F. Application of similarity factor in the

development of controlled release diltiazem tablet. Drug Dev Ind

Pharm 2000; 26: pp.723–730.

100. Ceulemans.J, Vinckier.I and Ludwig.A. The use of xanthan gum in an

ophthalmic liquid dosage form: rheological characterization of the

interaction with mucin. J. Pharm. Sci 2002; 91(4): pp. 1117–1127.

101. Jenkins. D.J, Wolever TM, Hockaday TD, et al. Treatment of diabetes

with guar gum: reduction of urinary glucose loss in diabetics. Lancet,

1977; ii: pp. 779–780.

102. Khullar. R, Khar. R.K and Agarwal SP. Guar gum as a hydrophilic

matrix for preparation of theophylline controlled-release dosage

form. Indian J. Pharm. Sci 1999; 61(6): pp. 342–345.

103. Feinstein. W and Bartilucci. A.J. Comparative study of selected

Disintegrating agents. J. Pharm. Sci. 1966; 55: pp. 332–334.

104. Sakr.A.M, Elsabbagh.H.M. Evaluation of guar gum as a tablet

additive: A preliminary report. Pharm Ind 1977; 39(4): pp. 399–403.

105. Adkin. D.A, Kenyon. C.J, Lerner. E.I, et al. The use of scintigraphy to

provide ‘‘proof of concept’’ for novel polysaccharide preparations

230

designed for colonic drug delivery. Pharm Res 1997; 14(1): pp.103–

107.

106. Wong. D, Larrabee. S, Clifford. K, et al. USP Dissolution Apparatus II

(reciprocating cylinder) for screening of guar based colonic delivery

formulations. Journal of Controlled Release, 1997; 47: pp.173–179.

107. Al-Saiden. S.M, Krishnaiah. Y.S, Satyanorayana. V, et al.

Pharmacokinetic evaluation of guar gum-based three-layer matrix

tablets for oral controlled delivery of highly soluble metoprolol

tartrate as a model drug. Eur J Pharm Biopharm 2004; 58(3): pp.

697– 703.

108. Verbeken.D, Dierckx.S and Dewettinck.K. Exudate gums:

occurrence, production, and applications. Appl Microbiol

Biotechnol . 2003; 63: pp.10-21.

109. Munday. D.L and Cox. P.J. Compressed xanthan and karaya gum

matrices: Hydration, erosion and drug release mechanisms. Int J

Pharm. 2000; 203: pp.179–92.

110. Park.C.R and Munday. D.L. Evaluation of selected polysaccharide

excipients in buccoadhesive tablets for sustained release of nicotine.

Drug Develop Ind Pharm. 2004; 30: pp.609–17.

111. Ceballos. A, Cirri. M, F. Maestrelli , G. Corti and P. Mura. Influence of

formulation and process variables on in vitro release of theophylline

from directly-compressed Eudragit matrix tablets IL Farmaco. 2005 ;

60, pp.913–918.

112. Ning Wua, Li-Shan.W, Darren Cherng Wen. T, Shabbir M.

Moochhalab and Y i-Yan Yanga. Mathematical modeling and in vitro

231

study of controlled drug release via a highly swellable and dissoluble

polymer matrix: polyethylene oxide with high molecular weights.

Journal of Controlled Release, 2005; 102, pp.569– 581

113. Shahla Jamzad and Reza Fassihi. Development of a controlled release

low dose class II drug-Glipizide. Int Journal of Pharmaceutics. 2006;

312, pp.24–32

114. Atul.K, Ashok. K. Tiwary, Narendra.K.Jain and Subheet Jain.

Formulation and In Vitro, In Vivo Evaluation of Extended- release

Matrix Tablet of Zidovudine: Influence of Combination of Hydrophilic

and Hydrophobic Matrix Formers AAPS Pharm Sci Tech, 2006; 7 (1),

E1-9

115. Per Borgquist , Anna. K , Lennart.P , Anette.L and Anders.A. A model

for the drug release from a polymer Matrix tablet effects of swelling and

dissolution. Journal of Controlled Release 113. 2006, pp. 216–225.

116. Celine.V. L, Lai Wah.C, Ching.A.L. and Sia Heng P. W. Evaluation of

sodium alginate as drug release modifier in matrix tablets. Int J

Pharm. 2006; pp. 25–37

117. Varshosaz.J, Naser .T and Fatemeh K. Use of hydrophilic natural

gums in formulation of sustained-release matrix tablets of tramadol

hydrochloride. AAPS PharmSciTech. 2006; 7 (1). Pp.1-6.

118. Sandra. F, Marzia. C, Francesca.M, Giovanna.C and Paola.M. Study of

formulation variables influencing the drug release rate from matrix

tablets by experimental design. European Jour. of Pharma. and

Biopharm. 2006; 62, pp. 77– 84.

232

119. Thawatchai. P and Garnpimol C. R. Formulation Variables

Influencing Drug Release from Layered Matrix System comprising

chitosan and xanthan gum. AAPS PharmSciTech. 2008; pp.870-877.

120. Hongtao. Li, Robert. J. H and Xiaochen. Gu. Effect of Drug

Solubility on Polymer Hydration and Drug Dissolution from Poly

(ethylene Oxide) Matrix Tablets. AAPS PharmSciTech, 2008;Vol. 9,

121. Praveen S. H and Ranendra N. S. Oral matrix tablet formulations for

concomitant controlled release of anti-tubercular drugs: design and in

vitro evaluations. International Journal of Pharmaceutics.2008; 362,

pp.118–125.

122. Rouslan.I.M , Evgeniya.B.M , Liliya F. S, Vera A. K & Guy Van den

Mooter. Comparative evaluation of interpolyelectrolyte complexes of

chitosan with Eudragit_ L100 and Eudragit_ L100-55 as potential

carriers for oral controlled drug delivery European Jour.of

Pharmaceutics and Biopharm.70 ,2008; pp.215–225.

123. Baojian. Wu, Daoyin. D, Yi Lu, Wei Wu. Biphasic release of

indomethacin from HPMC/pectin/calcium matrix tablet: II.

Influencing variables, stability and pharmacokinetics in dogs.

European Jour. of Pharmaceutics and Biopharm. 69 , 2008; pp.294–

302.

124. Sung.I.H and Seaung.Y.O. Dissolution kinetics and physical

characterization of three-layered tablet with poly(ethylene oxide) core

matrix capped by Carbopol. Int J Pharm.2008; 356, pp.121–129.

125. Hamdy. A, Ossama. Y. A and Hesham Salem. Formulation of

Controlled-Release Baclofen Matrix Tablets II: Influence of Some

233

Hydrophobic Excipients on the Release Rate and In Vitro Evaluation

AAPS Pharm Sci Tech,2007;9, No. 2, .pp. 156 – 166.

126. Jolly.M.Sankalia , Mayur.G.Sankalia and Rajashree.C. Mashru. Drug

release and swelling kinetics of directly compressed glipizide

sustained-release matrices: Establishment of level A IVIVC. Journal of

Controlled Release. 129, 2008, pp.49–58.

127. Dorottya. K , Károly. S and Romána Z. The effect of storage and active

ingredient properties on the drug release profile of poly(ethylene oxide)

matrix tablets. Carbohydrate Polymers.2008; 74, pp.930–933.

128. Anna .K, Anette. L, Andersson. ASA and Lennart P. Swelling and

Polymer Erosion for Poly(Ethylene Oxide) Tablets of Different

Molecular Weights Polydispersities. Journal of Pharmaceuticalical

sciences. 2009, 10.1002/.21892

129. Jelena. P, Jelena .J, Svetlana. I and Zorica Ð. Modelling of diclofenac

sodium diffusion from swellable and water- soluble polyethylene oxide

matrices Journal of Pharmacy and Pharmacology 2009; 61: pp.1449–

1456

130. Kanika.G, Nikhil. K and Anil. P. Formulation and evaluation of once-

daily sustained Release venlafaxine hydrochloride tablet using

Hydrophilic matrix. Journal of Pharmacy Research. 2009, 2(8),

pp.1287-1291.

131. Khemariya.P, Jain A.K, Bhargava.M, Singhai.S.K, Goswami. S and

Goswami. R. Preparation and in-vitro evaluation of sustained- release

matrix tablets of diltiazem. Int Journal of Advances in pharmaceutical

Sciences. 2010; pp.267-273.

234

132. Faith Chaibva , Michael Burton and Roderick B. Walker. Optimization

of salbutamol sulfate dissolution from sustained release matrix

formulations using an artificial neural network . Pharmaceutics, 2010,

2, pp.182–198.

133. Manish.G , Lee.A.H, Janet.B, Bridget.O.M, Fiona.J.M, Alexander.B.M

, Howard. N.E.S. In vitro and in vivo erosion profiles of

hydroxypropylmethylcellulose matrix tablets. Journal of Controlled

Release.2010: 147, pp.70–75.

134. Tomokazu.T, Shigeaki.M, Ryosaku.S, Masazumi.S, Shigeyuki Y,

Yukihiro O, Satoshi K. Release mechanisms of acetaminophen from

polyethyleneoxide/polyethylene glycol matrix tablets utilizing magnetic

resonance imaging International Journal of Pharmaceutics 395; 2010,

pp.147–153

135. Martti.M , Anneli.K , Heikki.A and Sirkka.N. The effect of food on

gastrointestinal transit and drug Absorption of a multiparticular

sustained-release verapamil. International Journal of Pharmaceutics.

1989; 53, pp.145-155.

136. Seham.A.E. Interaction of Verapamil hydrochloride with carbopol

934p and its effect on the release rate of the drug and the water

uptake of the polymer matrix. Drug Development and Industrial

Pharmacy, Vol 27, 2001; pp.925– 934.

137. Thomas. D and Reza F. Guar-based monolithic matrix systems: Effect

of ionizable and non-ionizable substances and excipients on gel

dynamics and release kinetics. Journal of controlled release. 80, 2002;

pp. 45–56.

235

138. Nadia.P, Beatrice.P, Beatrice.A, Dario.V, Mariarosa.M and

Lorenzo.R.C. Controlled release of verapamil hydrochloride from

waxy microparticles prepared by spray congealing Journal of

Controlled Release.2003; 88, pp. 263–275.

139. Munish.D, Poddar.S.S and Shajahan.A. Development of matrix and

coated units for pH independent release of weakly basic drug.

Pharmacy On line. 2003.

140. Mukesh.C.G, Tejas.P.P, and Shital.H.B. Studies in Preparation and

Evaluation of pH-Independent sustained-release matrix tablets of

verapamil Hcl using directly compressible eudragits. Pharmaceutical

Development and Technology.2003 Vol. 8, No.4, pp.323–333.

141. Aditya.S.T, Ketan.A.Mehta, Larry.A, Stephen.W.Hoag. Influence of

methacrylic and acrylic acid polymers on the release performance of

weakly basic drugs from sustained release hydrophilic matrices.

Journal of pharmaceutical sciences, 2004:Vol. 93, No. 9. pp.2319-

2331.

142. Omaima.N. El-Gazayerly, Vipaporn.R, and James W. Ayres. Novel

chewable sustained-release tablet containing verapamil hydrochloride.

Pharmaceutical Development and Technology. Vol. 9, No. 2, 2004;

pp.181–188.

143. Evren A, Muge. K, Ayşegul K, Nilufer Y and Tamer B. J. Fac. Pharm,

Ankara. 2004;33. pp. 125 - 137 .

144. Mohammad Reza Siahi, Mohammad Barzegar-Jalali, Farnaz

Monajjemzadeh, Fatemeh Ghaffari and Shirzad Azarmi. Design and

Evaluation of 1- and 3-Layer Matrices of Verapamil Hydrochloride for

236

Sustaining Its Release. AAPS PharmSciTech; 6 (4). 2005; pp. 626-

632.

145. George P & Nikolaos B. Swelling studies and in vitro release of

verapamil from calcium alginate and calcium alginate–chitosan

beads International Journal of Pharmaceutics.323. 2006. 34–42.

146. Sandile M. K and Roderick B. W. Evaluation of rate of swelling and

erosion of verapamil sustained release matrix tablets. Drug

Development and Industrial Pharmacy, 32:2006; pp.1139–1148.

147. Sasidhar. R.L.C, Vidyadhara. S and Srinivasa Babu. P. Development

of verapamil hydrochloride controlled release tablets using poly

(ethyleneoxides). The Indian Pharmacist. vol. 6, 2007; pp.96-98.

148. Tamara.G¸ Alves.A, Ali.R, Rajabi.S, Isidoro C. Application of

percolation theory in the study of an extended release Verapamil

hydrochloride formulation. International Journal of Pharmaceutics

361- 2008. pp.112– 117.

149. Durgacharan.A.B, Pravin.S.K and Dinesh.M.S. Sustained release

matrices of verapamil HCl using glyceryl monosterate and stearic acid

Research Jour. Pharm. and Tech. 2008: 1(4): pp.405-409.

150. Bistra.K, Elena.K and Ivo Ivanov, George. M and George.G.

Verapamil hydrochloride release characteristics from new copolymer

zwitterionic matrix tablets Pharmaceutical Development and

Technology, 2008,13: pp.311–321.

151. Gutsche.S. Strategies to overcome pH-dependent solubility of weakly

basic drugs by using different types of alginates. Drug Development

and Industrial Pharmacy, 2008: 34: pp.1277–1284.

237

152. Vishnu.M.Patel, Bhupendra.G.P and Anand.K.Patel. Controlled release

gastroretentive dosage form of verapamil hydrochloride International

Journal of PharmTech Research. 2009, Vol.1, No.2, pp 215- 221.

153. Durgacharan. A.B, Pravin. S. K and Dinesh M. Formulation and in

vitro evaluation of sustained release verapamil hydrochloride using

recirol ATO5 through melt granulation technique. Asian journal of

Pharmaceutics, 2009. pp. 278-285.

154. Kumud Kumar Padhy1, Kalpana Swain and K. A. Chowdary.

Influence of organic acids on drug release pattern of verapamil

hydrochloride pellets. Journal of Advanced Pharmaceutical

Research. 2010, 1, pp. 65-73.

155. Farhana SA, Shantakumar. S.M, Shyale. S, Shalam .M and Narasu L.

Sustained release of verapamil hydrochloride from sodium lginate

microcapsules. Current Drug Delivery. 2010Apr; 7 (2): pp.98- 108.

156. Shruti.C, Gayathri.V. P and Sanjay K. M. Release modulating

hydrophilic matrix systems of losartan potassium: Optimization of

formulation using statistical experimental design. European Journal of

Pharmaceutics and Biopharmaceutics.2007; 66, pp.73–82.

157. Sasidhar.R.L.C, Vidyadhara.S, Ramesh Babu.J, Nagaraju.R and

Prakash Reddy.K. Formulation and evaluation of controlled release of

losartan potassium matrix tablets using poly (ethylene oxides). Current

Trends in Biotechnology and Pharmacy.2009; Vol. 3, pp.320 – 328.

158. Prasant kumar.R and Bhabani Shankar.N. Formulation design,

preparation of losartan potassium microspheres by solvent

238

evaporation method and its in vitro characterization. Arch Pharm Sci

& Res. 2009; Vol 1, pp.166 –170.

159. Prajapati B.G. and Patel K.R. Once-daily sustained-release matrix

tablets of losartan potassium: Formulation and in vitro evaluation

International Journal of Medical and Clinical Research. 2009; Vol. 1,

Issue 1, pp.01-07.

160. Raju.D.B, Suresh John.K and Varma.M.M . Formulation and

evaluation of losartan potassium matrix tablets for oral controlled

release J. Chem. Pharm. Res., 2010, 2: pp.130-135.

161. Ravi sankar.V, Dastagiri Reddy.Y, Nageswara Rao.A and

Dhachinamoorthy.D and Chandra sekhar. K.B. Effect of

Hydrophylicand Hydrophobic Polymers on Losartan Potassium matrix

tablet. Journal of Pharmacy Research. 2010, 3(9), pp. 2195-2197.

162. Pavithra .T.K, Harshitha .R, Panneer .K, Renuka .S, Prakash Rao .B

and Narendra .C. Formulation and Evaluation of Hydrogel Based

Oral Controlled Drug Delivery System for Antihypertensive

Drug.Journal of Pharmaceutical Science and Technology.2010.Vol.2

(8), pp. 276-283.

163. Bistra K. and Dimitar R. New co-polymer zwitterionic matrices for

sustained release of verapamil hydrochloride. Acta Pharm. 2007, 57

;429–439

164. Indian Pharmacopoeia, Vol. II., 2007, p.1319.

165. United States Pharmacopoeia, 30th edn., Vol II., p.2499.

166. Yalcın Ozkan , Niyazi Yılmaz , Sibel A. O and Inci B. High-performance

liquid chromatographic analysis of verapamil and its application to

239

determination in tablet dosage forms and to drug dissolution studies.

Il Farmaco. 2000, 55; pp.376–382

167. Deanne.L. Hertzog.A, Jennifer Finnegan McCafferty B, Xueguang

Fang b, Jeffrey Tyrrell c, Robert A. Reed. Development and validation

of a stability indicating HPLC method for the simultaneous

determination of Losartan potassium, hydrochlorothiazide, and their

degradation products. Journal of Pharma. and Biomedical Analysis.

2002; 30, pp.747–760

168. Quality control. 4 th ed. Pharmaceutical statistics: Practical and

clinical applications. In: Bolton S, Bon C, editors. New York: Marcel

Dekker: 2004. p.408-411.

169. Moore.J.W. and Flanner.H.H. Mathematical comparison of dissolution

profiles. Pharm. Tech. 1996 20, pp.64–74.

170. ICH, QIA Stability testing of new dosage forms. International

conference on Harmonization, Geneva, October. 1993.

171. Peck.G.E, Baley.G.J, McCurdy.V.E and Banker.G.S. Tablet

formulation and design. Pharmaceutical Dosage Forms, Tablets 2nd

Ed, Marcel Dekker, New York 1989; 109-112.

172. Raymond C Rowe, Paul .J. S, Sian C. O. Handbook of Pharmaceutical

Excipients, Pharmaceutical Press, Fifth edition, 2006; Pp 656-658.